Navigation Links
Angioslide Closes US$8.6million Series C Financing
Date:6/2/2008

HERZLIYA, Israel, June 2 /PRNewswire/ -- Angioslide, Ltd. today announced the closing of an US$8.6 million Series C financing round. Angioslide is the developer of the unique Angioslide eXtra(TM) angioplasty balloon catheter that provides dual functionality in a single device offering balloon angioplasty with embolic protection. The device has received European CE Mark approval for lower limb use and FDA clearance is expected by end of 2008. The financing will be used to support sales and marketing efforts in the U.S. and Europe as well as for continuous development of expanded market applications. European sales activities shall commence September 2008.

Itochu Corporation, Japan, led this second round of financing with support from Ofer Hi-Tech, Israel and Viola Partners, Israel, who both participated in the previous financing round.

The Angioslide eXtra balloon angioplasty catheter offers balloon angioplasty with embolic particle capture creating a first of its kind device. When performing Angioplasty physicians typically take a two-step approach using both an embolic protection device and a balloon angioplasty catheter. The Angioslide eXtra takes this two-step, two-device process and reduces it to one single instrument, used for one single procedure, with a minimized procedure time and significantly reduced costs.

"After 30 years of balloon angioplasty, this is the first time that a balloon can do more than standard inflation and deflation and the response from the medical community has been remarkable. Imagine a lower limb angioplasty product that functions as both a balloon catheter and an embolic protection device," said Doron Besser, CEO of Angioslide. "With the increasing amount of procedures being performed in the lower limbs and other peripheral regions causing a higher rate of embolic events, it is clear from capitol infusion we have received that the Angioslide eXtra is addressing an unmet need. I can't think of a better qualified investor group to partner with than, Itochu, Ofer Hi-tech and Viola, as we look to FDA approval later this year and initiating European and U.S. sales."

"We are very proud of the first involvement with the Itochu Corporation. The strong management team coupled with an innovative product offering promises to change the landscape of angioplasty and peripheral vascular disease treatment," said Lihu Avitov, Executive Vice President, Ofer Hi-Tech.

About Angioslide, Ltd. Angioslide was founded in 2005 in Herzliya, Israel. They have developed a unique angioplasty balloon catheter that has dual functionality in a single device: balloon angioplasty with embolic protection. The Angioslide eXtra addresses an unmet need for an easy-to-use, efficient and cost-effective embolic protection solution for the peripheral vascular disease market. It is the first device of its kind to seek FDA clearance for use in lower limbs. The device has received European CE Mark approval for lower limb use with FDA clearance expected by end of year 2008 followed by application for renal use. For more information contact Doron Besser at doronb@angioslide.com.

Contact:

Doron Besser

+972-9-955-6500

doronb@angioslide.com


'/>"/>
SOURCE Angioslide Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. 2008 Bank of America Chicago Marathon Registration Closes as Race Reaches 45,000 Participant Capacity
2. Health Plan One Closes $6.5 Million Series A Financing
3. MM2 Group Closes Sale for New Venture in China
4. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
5. China Sky One Medical, Inc. Closes Acquisition of Heilongjiang Tianlong Pharmaceutical, Inc.
6. Breathe Technologies, Inc. Closes on $15 Million in Venture Funding Led by Kleiner Perkins Caufield & Byers
7. Alimera Sciences Closes $30 Million in Series C Financing, Increasing Stake in Medidur(TM) FA
8. Allegro Diagnostics Closes $4 Million Round to Develop and Commercialize Lung Cancer Molecular Diagnostics Based on Gene Expression
9. Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes
10. DATATRAK Closes Second Multi-Year Enterprise Agreement with European Clinical Trial Sponsor
11. Bacterial toxin closes gate on immune response, Penn researchers discover
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute Valentine’s Day ... tips of your toes. Foot massage, whether administered by a professional masseuse or a ... The American Board of Multiple Specialties in Podiatry (ABMSP) has taken the ...
(Date:2/5/2016)... Florida (PRWEB) , ... February 05, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – is poised to once again host, Swirl, A Wine Tasting Event at ...
(Date:2/5/2016)... ... 05, 2016 , ... The American public tends to feel uncomfortable about drinking ... regular municipal or well water. The recent experience with lead contaminated water in Flint, ... long way toward increasing public acceptance of recycled waste water as drinking water. ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of the ... this weekend’s Big Game. Take the stress out of your party preparation – follow ... happy at every stage of the game. , “The key to hosting a successful ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Dr. Justin ... announce their 2nd Annual No Cost Dental Day to individuals in need. The event ... purpose of this No Cost Dental Day is to provide dental care to community ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Feb. 4, 2016  Edwards Lifesciences Corporation (NYSE: ... structural heart disease and critical care monitoring, announced today ... (ASR) agreement with Morgan Stanley & Co. LLC to ... is part of the Company,s previously authorized program to ... stock.  --> --> ...
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
Breaking Medicine Technology: